We’re improving your experience
Some features may be temporarily limited due to scheduled maintenance.
Normal service will resume on 24/11. We apologize for the inconvenience.

Investing for tomorrow

Discover our Insights

  • USD 183bn*

    Assets under supervision as at 30 June 2025

  • 25

    years of ESG experience

*As of 30/06/2025. As of 31/12/2022, Candriam changed the Assets Under Management (AUM) calculation methodology, and AUM now includes certain assets, such as non-discretionary AUM, external fund selection, overlay services, including ESG screening services, advisory consulting services, white labelling services, and model portfolio delivery services that do not qualify as Regulatory Assets Under Management, as defined in the SEC’s Form ADV. AUM is reported in EUR. AUM not denominated in EUR is converted at the spot rate as of 30/06/2025.

Important Message: Beware of Impersonation Scams

Fraudulent messages and advertisements are currently circulating on messaging platforms, including WhatsApp, impersonating Candriam’s brand and investment professionals. Please note that Candriam never offers investment recommendations or provides financial advice through social media channels or messaging platforms.

You are browsing from the United States! Would you like to change your location?
Ken Van Weyenberg, Oncology, ESG, SRI, Healthcare

Why oncology remains a key investment opportunity

The investment landscape is marked by persistent macroeconomic uncertainties, uneven growth, and heightened geopolitical risks. Despite attractive earnings growth, healthcare has also been under pressure due to regulatory restructuring, drug pricing debates, budget constraints, and tariff concerns.
CSR Report 2024
Weekly Views
What's next

Latest Insights

  • Private Debt

    Private Debt: Predictable Real Returns

    Does it seem as though we, and our investments, are living in uncertain times? With its scheduled cash flows, private debt may provide a predictable and reliable instrument within your overall asset allocation.
  • Research Paper, Alix Chosson, Elouan Heurard, ESG, SRI, Biodiversity

    Can We Assess Companies’ Ecological Debt? And How?

    While, according to the World Economic Forum, half of the global GDP is dependent on nature, biodiversity is experiencing an extinction that challenges the resilience of our economies. Deterioration of air, water and soil quality, decline in ecosystem services such as pollination: the physical impacts of this loss of biodiversity are already putting our economies under pressure.
  • Healthcare, ESG, SRI

    Why healthcare, why now?

    On Tuesday, September 30, the pharmaceutical industry issued its first formal response to President Trump’s recent letter on drug pricing, announcing a deal between Pfizer and the US administration.
  • ESG, SRI, Oncology, Healthcare

    From uncertainty to growth: why invest in healthcare?

    As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
  • Private Debt

    Private Debt: The Lower-Mid-Market Niche

    The lower-mid-market segment of Private Debt offers potentially attractive returns and the ability to manage risk through greater selectivity and better control. Yet, success requires experience and market presence.
Insights
“At Candriam, we embrace Conviction and Responsibility in everything we do.”
Vincent Hamelink, CEO

Expertise

Thematic

Find it fast

Get information faster with a single click

Get insights straight to your inbox